<DOC>
	<DOC>NCT00976508</DOC>
	<brief_summary>This is a Phase 1 study investigating the safety and tolerability of Figitumumab plus Pegvisomant for treatment of advanced solid tumors.</brief_summary>
	<brief_title>Figitumumab Combined With Pegvisomant For Advanced Solid Tumors</brief_title>
	<detailed_description>This study was closed to enrollment on 18 April 2011 due to inability to recruit patients on a timely basis as well as business reasons. Study closure was not related to any safety concerns.</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Lung Neoplasms</mesh_term>
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Patients ≥18 years of age with advanced solid tumors for which the combination of figitumumab and pegvisomant are reasonable treatment options. Patients between the ages of 10 and 18 years with advanced sarcomas for which there is no available curative therapy or therapy proven to prolong survival with an acceptable quality of life will be included in the Sarcoma Expansion Cohort. Adequate recovery from prior therapies. Adequate organ function (i.e. bone marrow, kidney, liver) Total IGF1 ≥100 ng/ml (13 nmol/L). Concurrent treatment with any antitumor agents. Pregnant or breastfeeding females. Significant past history or active cardiac disease Active infection History of diabetes mellitus. Glycosylated hemoglobin &gt;5.7</criteria>
	<gender>All</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>October 2013</verification_date>
	<keyword>advanced solid tumors cancer refractory cancer figitumumab pegvisomant</keyword>
</DOC>